Stockreport

Revance Doses First Patient in ASPEN Phase 3 Clinical Program of RT002 Injectable for the Treatment of Cervical Dystonia

Revance Therapeutics, Inc.  (RVNC) 
Last revance therapeutics, inc. earnings: 2/24 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.revance.com
PDF - RT002 Injectable has potential to be first long-acting neuromodulator for treatment of a debilitating involuntary muscle movement disorder - NEWA [Read more]